Skip to search formSkip to main contentSkip to account menu

ICA 17043

Known as: ICA-17043, ICA17043 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

senicapoc

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
KCa3.1 K+ Channel Expression and Function in Human Bronchial Epithelial Cells
The KCa3.1 K+ channel has been proposed as a novel target for pulmonary diseases such as asthma and pulmonary fibrosis. It is… 
2011
2011
T5 The KCa3.1 K+ channel mediates wound healing in human myofibroblasts
Idiopathic pulmonary fibrosis (IPF) is a common progressive interstitial lung disease and current treatments are ineffective. The… 
2008
2008
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Commentary
Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC… 
2004
2004
Efficacy and Safety of the Gardos Channel Inhibitor, ICA-17043, in Patients with Sickle Cell Anemia.
The rate and extent of hemoglobin S (HbS) polymer formation in the circulating sickle erythrocyte (RBC) is strongly influenced by… 
2003
2003
ICA-17043: Treatment of sickle cell disease Gardos channel inhibitor
Sickle cell disease is a genetic hematologic condition characterized by the presence of abnormal hemoglobin within red blood… 
2000
2000
A phase i safety, pharmacokinetic, and pharmacodynamic study of ascending single, oral doses of ICA-17043, a novel gardos channel inhibitor for the treatment of sickle cell disease
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)